General American Investors’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-1,839,424
| Closed | -$4.07M | – | 72 |
|
|
2023
Q2 | $4.07M | Sell |
1,839,424
-75,000
| -4% | -$156K | 0.35% | 54 |
|
|
2023
Q1 | $4.86M | Buy |
1,914,424
+30,031
| +2% | +$59.3K | 0.46% | 46 |
|
|
2022
Q4 | $3.52M | Sell |
1,884,393
-31,706
| -2% | -$79K | 0.34% | 50 |
|
|
2022
Q3 | $4.92M | Buy |
1,916,099
+163,629
| +9% | +$407K | 0.51% | 46 |
|
|
2022
Q2 | $3.38M | Buy |
1,752,470
+304,300
| +21% | +$664K | 0.34% | 52 |
|
|
2022
Q1 | $4.3M | Buy |
1,448,170
+141,251
| +11% | +$531K | 0.35% | 55 |
|
|
2021
Q4 | $5.87M | Buy |
1,306,919
+194,261
| +17% | +$922K | 0.46% | 53 |
|
|
2021
Q3 | $5.41M | Buy |
1,112,658
+71,461
| +7% | +$394K | 0.46% | 56 |
|
|
2021
Q2 | $7.1M | Buy |
1,041,197
+54,602
| +6% | +$441K | 0.59% | 51 |
|
|
2021
Q1 | $6.96M | Sell |
986,595
-14,156
| -1% | -$102K | 0.65% | 48 |
|
|
2020
Q4 | $6.26M | Hold |
1,000,751
| – | – | 0.62% | 47 |
|
|
2020
Q3 | $5.41M | Buy |
1,000,751
+145,038
| +17% | +$718K | 0.62% | 45 |
|
|
2020
Q2 | $4.47M | Buy |
855,713
+52,529
| +7% | +$233K | 0.57% | 45 |
|
|
2020
Q1 | $2.53M | Buy |
803,184
+158,861
| +25% | +$586K | 0.34% | 50 |
|
|
2019
Q4 | $2.6M | Sell |
644,323
-105,337
| -14% | -$365K | 0.24% | 60 |
|
|
2019
Q3 | $3.24M | Buy |
749,660
+279,475
| +59% | +$1.12M | 0.32% | 56 |
|
|
2019
Q2 | $1.88M | Buy |
470,185
+5,200
| +1% | +$24.7K | 0.18% | 66 |
|
|
2019
Q1 | $2.49M | Hold |
464,985
| – | – | 0.25% | 64 |
|
|
2018
Q4 | $2.38M | Buy |
464,985
+28,621
| +7% | +$217K | 0.25% | 62 |
|
|
2018
Q3 | $4.23M | Buy |
436,364
+50,000
| +13% | +$504K | 0.36% | 57 |
|
|
2018
Q2 | $3.94M | Buy |
386,364
+77,500
| +25% | +$877K | 0.36% | 59 |
|
|
2018
Q1 | $4.01M | Hold |
308,864
| – | – | 0.38% | 59 |
|
|
2017
Q4 | $5.53M | Sell |
308,864
-38,349
| -11% | -$800K | 0.54% | 51 |
|
|
2017
Q3 | $8.71M | Buy |
347,213
+40,000
| +13% | +$931K | 0.83% | 46 |
|
|
2017
Q2 | $7.4M | Hold |
307,213
| – | – | 0.75% | 47 |
|
|
2017
Q1 | $5.91M | Buy |
307,213
+44,037
| +17% | +$694K | 0.58% | 52 |
|
|
2016
Q4 | $4.05M | Sell |
263,176
-277,076
| -51% | -$3.6M | 0.41% | 54 |
|
|
2016
Q3 | $7.03M | Buy |
540,252
+63,176
| +13% | +$838K | 0.72% | 49 |
|
|
2016
Q2 | $6.64M | Buy |
477,076
+200,000
| +72% | +$2.94M | 0.69% | 47 |
|
|
2016
Q1 | $4.2M | Hold |
277,076
| – | – | 0.43% | 49 |
|
|
2015
Q4 | $5.26M | Hold |
277,076
| – | – | 0.48% | 50 |
|
|
2015
Q3 | $5.26M | Hold |
277,076
| – | – | 0.47% | 50 |
|
|
2015
Q2 | $7.14M | Buy |
277,076
+210,441
| +316% | +$5.97M | 0.59% | 50 |
|
|
2015
Q1 | $2.08M | Buy |
+66,635
| New | +$1.91M | 0.17% | 57 |
|
General American Investors's PRTK Position: Q3 2023 in Review
General American Investors sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2023, closing a stake of 1,839,424 shares — an estimated $4.07M sold.
General American Investors first reported a position in PRTK in Q1 2015 and held it in 34 quarters. The position peaked at $8.71M in Q3 2017. 0 funds tracked by Wall St. Rank hold PRTK as of Q3 2023.
- General American Investors reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
- General American Investors sold 1,839,424 Paratek Pharmaceuticals, Inc. shares in Q3 2023, an estimated $4.07M.
- General American Investors first reported a position in Paratek Pharmaceuticals, Inc. in Q1 2015 and held it in 34 quarters.
- General American Investors's Paratek Pharmaceuticals, Inc. position peaked at $8.71M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2023.
Based on General American Investors's 13F filing for Q3 2023, filed 31 Oct 2023.